<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441961</url>
  </required_header>
  <id_info>
    <org_study_id>mtx in eosinophilic fasciitis</org_study_id>
    <nct_id>NCT00441961</nct_id>
  </id_info>
  <brief_title>Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis</brief_title>
  <official_title>Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of high dose MTX on skin induration in patients with eosinophilic fascia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eosinophilic fasciitis (EF)is a fibrosing skin disorder extensively involving the deep
      fascia. The aim of this pilot study is to evaluate the effect of high dose MTX on skin
      induration in patients with EF. In addition, we study the effect of this treatment on joint
      mobility, peripheral blood eosinophilia, functional ability, and pulmonary function. By
      administering high dose MTX intravenously every four weeks with a Leukovorin rescue, we hope
      to induce a more pronounced and sustained effect on the involved skin with less
      (long-lasting) side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy is evaluated after 6 months.</measure>
    <time_frame>December 2008</time_frame>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Fasciitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>methotrexate</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eosinophilic fasciitis as defined by clinical judgement of an expert,

          -  Histologically confirmed with a skin-fascia-muscle biopsy, and in additon:

               -  Either the presence of a modified skin score according to Zachariae of 8 or
                  higher (0-18), regarded as a generalised eosinophilic fasciitis or the presence
                  of severe contractures due to eosinophilic fasciitis lesions.

        Exclusion Criteria:

          -  Age &lt; 18 yrs

          -  Contraindications to MTX: AST/ALT level &gt; 2 times upper limit of normal, WBC count &lt;
             3.5 x 109/l or platelet count &lt; 150 x 109/l, serum creatinine &gt; 130 micromol/l or
             clearance &lt; 50 ml/min, confirmed by two repeated tests within one month.

          -  Chronic liver disease, insulin dependant diabetes mellitus, alcohol abuse

          -  Restrictive pulmonary disease (total lung capacity or vital capacity &lt; 40% of
             predicted) or interstitial lung disease (KCO &lt; 60% of predicted)

          -  Pregnancy or child bearing potential without adequate contraception

          -  The presence of any serious co-morbidity or malignancy

          -  Use of other anti-folate drugs than MTX
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Knaapen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>H. Knaapen, MD</name_title>
    <organization>Radboud University</organization>
  </responsible_party>
  <keyword>Eosinophilic fasciitis, Shulman's syndrome, methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

